

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—DP24–031, Epidemiologic Cohort Study of Interstitial Cystitis.

*Date:* April 10, 2024.

*Time:* 10 a.m.–6 p.m., EDT.

*Place:* Teleconference/Web Conference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Catherine Barrett, Ph.D., Scientific Review Officer, National Center for

Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop S106–3, Atlanta, Georgia 30341–3717. Telephone: (404) 718–7664; Email: [CBarrett@cdc.gov](mailto:CBarrett@cdc.gov).

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**  
*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2024–02514 Filed 2–7–24; 8:45 am]

**BILLING CODE 4163–18–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Food and Drug Administration**

[Docket Nos. FDA–2023–N–2894; FDA–2023–N–1929; FDA–2017–N–5569; FDA–2023–N–2564; FDA–2023–N–2851; FDA–2023–N–1554]

**Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, [PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at <https://www.reginfo.gov/public/do/PRAMain>. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB

Title of collection	OMB control No.	Date approval expires
Good Laboratory Practice (GLP) Regulations for Nonclinical Laboratory Studies .....	0910–0119	1/31/2027
Orphan Drugs .....	0910–0167	1/31/2027
Medical Devices; Device Tracking .....	0910–0442	1/31/2027
Channels of Trade Policy for Commodities with Residues of Pesticide Chemicals for Which Tolerances Have Been Revoked, Suspended, or Modified by the EPA .....	0910–0562	1/31/2027
Time and Extent Applications for Nonprescription Drug Products .....	0910–0688	1/31/2027
Qualitative Feedback on Food and Drug Administration Service Delivery .....	0910–0697	1/31/2027

Dated: February 5, 2024.

**Lauren K. Roth,**  
*Associate Commissioner for Policy.*

[FR Doc. 2024–02579 Filed 2–7–24; 8:45 am]

**BILLING CODE 4164–01–P**